Sun Pharma Approves Up to ₹10,000 Crore NCD Issuance; Director Resigns
Sun Pharmaceutical Industries Ltd · Change in Management · 13 Oct 2026, 1:34 am
Sun Pharma Approves Up to ₹10,000 Crore NCD Issuance; Director Resigns Sun Pharmaceutical Industries' Board approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures (NCDs) on a private placement basis for up to ₹10,000 Crore in one or more tranches. The Board also authorized its Finance Committee to finalize tranche-specific terms and allotment details. Additionally, Non-Executive Independent Director Gautam Doshi resigned with immediate effect on 12th Oct'26, citing personal commitments, simultaneously stepping down from board committees and subsidiary directorships with no other material reasons reported.
Original exchange filing (PDF)
More announcements from Sun Pharmaceutical Industries Ltd
- Intimation of Schedule of Analyst/Institutional Investor Meeting · 05 Nov 2026
- Q2FY27 Earnings Call Transcript · 05 Nov 2026
- Clarification regarding news report relating to the Company''s Assam facility · 03 Nov 2026
- The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting .... · 02 Nov 2026
- Completion and results of postal ballot dated 01 October 2026 · 01 Nov 2026
- Q2FY27- Investor Call Audio Recording · 31 Oct 2026
- Board Meeting Outcome - Conclusion · 30 Oct 2026
- Unaudited Financial Results for the quarter and half year ended 30 September 2026 · 30 Oct 2026
